Are black and Hispanic persons disproportionately affected by COVID-19 because of higher obesity rates?

Maher El Chaar1, Keith King2, Alvaro Galvez Lima2

  • 1St Luke's University Hospital and Health Network, Bethlehem, Pennsylvania; Temple Lewis Katz School of Medicine, Philadelphia, Pennsylvania.

Insights

Black and Hispanic populations in New York City experienced higher COVID-19 mortality rates. Higher obesity rates in these ethnic groups may be a contributing factor to the increased mortality during the pandemic.

Area of Science:

  • Public Health
  • Epidemiology
  • Health Disparities

Background:

  • The COVID-19 pandemic disproportionately impacted New York City (NYC), with initial reports indicating higher mortality in Black and Hispanic communities.
  • Understanding the factors contributing to these disparities is crucial for public health interventions.

Purpose of the Study:

  • To investigate the relationship between COVID-19 mortality rates and obesity rates across different ethnic groups and boroughs in NYC.
  • To determine if obesity prevalence warrants further evaluation as a potential factor in ethnic disparities in COVID-19 outcomes.

Main Methods:

  • Utilized official NYC COVID-19 data on cases and age-adjusted mortality rates by ethnic group.
  • Cross-referenced COVID-19 data with historical community health data on obesity rates across different ethnic groups and boroughs.

Main Results:

  • The Bronx and Brooklyn had the highest COVID-19 mortality rates (6% and 5.4%) and the highest obesity rates (32% and 27%, respectively).
  • Hispanic and Black populations exhibited the highest obesity rates and consequently the highest age-adjusted COVID-19 mortality rates per 100,000 (22.8% and 19.8%).

Conclusions:

  • Hispanic and Black populations in NYC faced disproportionately higher COVID-19 mortality.
  • Elevated obesity rates within these ethnic groups may have significantly contributed to the observed higher mortality incidence.
Abstract

Related Concept Videos

Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
156
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.0K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
158
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
115
Bias in Epidemiological Studies01:29

Bias in Epidemiological Studies

Biases can arise at various stages of research, from study design and data collection to analysis and interpretation. Recognizing and addressing these biases is essential to ensure the validity and reliability of epidemiological findings.Broadly speaking, biases in epidemiology fall into three main categories: selection bias, information bias, and confounding. A more detailed description of possible biases is:  
1.1K
Stress Prevention and Stress Management Techniques IV01:26

Stress Prevention and Stress Management Techniques IV

Stress often leads to unhealthy habits like smoking, excessive drinking, and overeating, which offer short-term relief but ultimately increase long-term health risks. These behaviors create a cycle that temporarily lowers stress levels but can result in severe long-term health consequences. Breaking these habits is essential to reduce the risk of chronic diseases and improve overall well-being. Three primary changes that support better health include quitting smoking, reducing alcohol intake,...
176